Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference
18 11월 2019 - 6:30AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that the company will participate in
the AACR Tumor Immunology and Immunotherapy conference at the
Boston Marriott Copley Place in Boston, MA, November 17-20,
including poster presentations on November 18th and 19th.
The company will showcase ImmunoID NeXT™, the first platform to
enable comprehensive analysis of both a tumor and its immune
microenvironment from a single sample. ImmunoID NeXT™ can be used
to investigate the key tumor- and immune-related areas of cancer
biology, consolidating multiple oncology biomarker assays into one
and maximizing the biological information that can be generated
from a precious tumor specimen.
Following is a list of abstracts that will be presented at the
meeting.
Scientific Poster Presentations
Poster Number
Title & Presenter
Day & Time
Location
A19
HLA allele-specific loss of
heterozygosity detection using augmented exome capture approach
Presenter: Rachel Marty Pyke, Ph.D.
November 18: 12:30 PM – 3:00 PM
Back Bay
B18
Exome scale liquid biopsy monitoring of
putative neoantigens and genomic biomarkers in patients on
anti-PD-1 therapy in squamous cell carcinoma of the head and
neck Presenter: Charles Abbott, Ph.D.
November 19: 4:30 PM – 7:00 PM
Back Bay
Personalis will also be exhibiting during the conference
(Exhibit # 10). Representatives will be available to answer
questions about the company’s cancer immunogenomics services.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191117005063/en/
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024